Evaluating the Therapeutic Mechanisms of Selected Active Compounds in *Houttuynia cordata* Thunb. in Pulmonary Fibrosis via Network Pharmacology Analysis

De-Wei Zhu†, Qun Yu†, Ji-Jia Sun† and Yun-Hui Shen*

School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Pulmonary fibrosis, a common outcome of pulmonary interstitial disease of various different etiologies, is one of the most important causes of respiratory failure. *Houttuynia cordata* Thunb. (family: Saururaceae) (*H. cordata*), as has been reported, is a Chinese herbal medicine commonly used to treat upper respiratory tract infection and bronchitis. Our previous study has proven that sodium houttuyfonate (an additional compound from sodium bisulfite and houttuynin) had beneficial effects in the prevention of pulmonary fibrosis (PF) induced by bleomycin (BLM) in mice. In the present study, network pharmacology was used to investigate the efficiency and potential mechanisms of *H. cordata* in PF treatment. Upon manual collection from the literature and databases such as TCMSP and TCM-ID, 10 known representative ingredients of *H. cordata* species were screened. Then, the prediction of the potential active ingredients, action targets, and signaling pathways were conducted through the Gene Ontology (GO), protein–protein interaction (PPI), and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. The results of network pharmacology prediction suggested that *H. cordata* may act through multiple signaling pathways to alleviate PF, including the phosphatidylinositol 3-kinase-protein kinase B (PI3K/AKT) pathways, mitogen-activated protein kinase (MAPK) pathways, the tumor necrosis factor (TNF) pathways, and interleukin-17 (IL-17) signaling pathways. Molecular docking experiments showed that the chemical constituents of *H. cordata* had good affinity with TNF, MAPK1, and AKT1, and using lipopolysaccharide (LPS)-induced A549 cells, a model was established to verify the anti-pulmonary fibrosis effects and related mechanisms of *H. cordata*–relevant constituents. Finally, these evidences collectively suggest *H. cordata* may alleviate PF progression via PI3K/Akt, MAPK, and TNF signaling pathways and provide novel insights to verify the mechanism of *H. cordata* in the treatment of PF.

Keywords: pulmonary fibrosis, *Houttuynia cordata* Thunb., molecular mechanism, network pharmacology, signaling pathway analysis
INTRODUCTION

Pulmonary fibrosis (PF) is a chronic, progressive, and devastating interstitial lung disease mainly resulting from toxic insults, autoimmune injuries, drug-induced injuries, infectious injuries, or traumatic injuries. As can be affected by age, genetic predisposing factors, and environmental exposures, PF produces many different pathological types, which are mainly classified as idiopathic pulmonary fibrosis (IPF) and fibrosing alveolitis. PF is mainly characterized by diffuse pneumonia in the early period, secreting pro-inflammatory cytokines such as the tumor necrosis factor α (TNF-α), interleukin-1β (IL-1β), and IL-6. Alveolar epithelial cell (AEC) injury and excessive deposition of collagen in extracellular matrix (ECM) ultimately result in progressive scarring and loss of lung function (Wynn and Vannella, 2016). With approximately 3 million people being affected worldwide, as shown in the related literature, IPF has an increasing burden (George et al., 2020). At present, there is no effective means or drugs that can ameliorate PF except lung transplantation in patients with a median survival of 3–5 years from the time of diagnosis (Meyer, 2017).

PF, with clinical manifestations such as progressive dyspnea, cough, sputum, chest pain, vomiting, dry mouth, dry throat, shortness of breath, and fatigue, was defined as "lung impediment" or "lung wilting" in books of traditional Chinese medicine, and its syndrome types were divided into lung–kidney Qi deficiency (Fei shen qi xu), dual deficiency of the lung and spleen (Pi fei liang xu), Qi deficiency with blood stasis (Qi xu xue yu), and phlegm obstructing the vessels and collaterals (Tan zu mai luo). They were mainly treated by methods of invigorating the lungs and kidneys (Bu fei yi shen), fortifying the spleen and boosting the lung (Jian pi yi shen), and harmonizing and percolating dampness (He jie shen shi). The treatment process used decoctions including Schisandra thunb), and harmonizing and percolating dampness (He jie shen shi). The treatment process used decoctions including Schisandra (family: Saururaceae) (L.) Urban, Ophiopogon japonicus (L.f) Ker-Gawl., and Houttuynia cordata Thunb. (family: Saururaceae) (H. cordata). The traditional Chinese medicine (TCM) mainly produces synergistic effects via the synergistic mechanism of actions with the active ingredients, enhancing functions, and producing less toxicity, which makes enormous contributions to modern drug development and disease treatment. Some active ingredients in the traditional Chinese medicine play a good role in the progression of PF, just like paclitaxel (PTX) (Wang et al., 2013), tanshinone IIA (Tan IIA) (He et al., 2015), and andrographolide (Andro) (Guo et al., 2016).

H. cordata, famous in China, Japan, Korea, and Northeast India for its medicinal properties, is used in the treatment of a number of diseases such as pneumonia, diabetes, and even SARS (Lau et al., 2008). Studies have found that H. cordata also has a certain inhibitory effect on PF; for instance, the volatile oil of H. cordata contains 4-terpineol, α-terpineol, l-bornyl acetate, and methyl-α-nonyl ketone, and has good anti-inflammatory and anti-pulmonary fibrosis effects in vitro and in vivo (Du et al., 2012). The aqueous extract of H. cordata has effects of anti-pulmonary fibrosis by inhibiting the expression of superoxide dismutase, malondialdehyde, hydroxyproline, interferon-γ (IFN-γ), and TNF-α (Ng et al., 2007). Qing fei xie ding granules (Sun et al., 2018), mainly including Ephedra sinica, apricot kernels, and H. cordata, have a protective effect on PF as a novel Chinese traditional patent medicine. However, the anti-pulmonary fibrosis mode and the mechanism of action of H. cordata are not fully clarified. To address the protective effects of H. cordata on PF, our previous study has shown that sodium houttuyfonate is an attractive candidate alleviating IPF and pulmonary toxicity induced by BLM through downregulation of TGFβ1-Smad2/3 signal transduction (Shen et al., 2021).

Despite the obvious medicinal effects and clinical uses of TCM, little has been elucidated regarding the underlying molecular mechanisms. Network pharmacology integrates several disciplines, including systems biology, network biology, computational biology, multi-target pharmacology, and molecular pharmacology. And the core is the construction of a drug molecule–target–disease link network and the systematic analysis of the three relationships. It can be used to predict active molecules and actions of TCM, and then to search for new pharmaceutical mechanisms of action and broaden the indications of TCM, etc. Molecular docking is used to design drugs by in silico modeling of the interaction of target proteins with drug molecules. Molecular docking has been gradually applied to reveal the relevant mechanism of action of drugs in the development of new drugs. This study aims to utilize network pharmacology and molecular docking to seek the active compounds of H. cordata, construct the drug–compounds–genes–disease network, and to analyze the underlying mechanism of H. cordata in the treatment of PF.

METHODS

Main Candidate Active Ingredients and Targets of H. cordata

The keyword “Houttuyniae Herba” was searched in TC MSP (traditional Chinese medicine systems pharmacology database and analysis platform, http://tcmsp.com/tcmsp.php) and TCM-ID (traditional Chinese medicine integrated database, http://www.megabionet.org/tcmid/). Active ingredients were retrieved from them. The chemical information of main active ingredients was collected from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and the Canonical SMILES of all ingredients were traced back to PubChem (http://pubchem.ncbi.nlm.nih.gov). The major components in H. cordata were obtained by a literature review and screening of public databases. The potential therapeutic targets of the main active components were predicted by matching them in the TC MSP, SEA (https://sea.bkslab.org/), HitPick (http://mips.helmholtz-muenchen.de/hitpick/), SwissTargetPrediction (http://www.swisstargetprediction.ch/), and STITCH (http://stitch.embl.de/) tools. Among them, according to TC > 0.4 in SEA, according to precision >50% SwissTargetPrediction in HitPick, the top 15 with the highest scores were selected, and according to score >0.4 in stitch.

Mining of Pulmonary Fibrosis–Related Targets

With “pulmonary fibrosis” as the keyword, DisGeNET (https://www.disgenet.org/), GeneCards (https://www.
potential disease target analysis platforms were utilized to search for human genes related to PF. After data deduplication/integration, intersecting genes were obtained and considered as therapeutic targets relevant to PF.
Drug–Target–Disease Network Construction

Active ingredients of *H. cordata*–related targets and PF-related targets were imported into the Venn online tool (http://www.bioinformatics.com.cn/) to obtain the intersection and a Venn diagram, in which potential targets of *H. cordata* for the treatment of PF were revealed. The above potential target gene ID was identified and standardized through the UniProt database (https://www.uniprot.org). The target network of *H. cordata* major ingredients acting on PF was analyzed by Cytoscape 3.7.1 built-in tools.

Protein–Protein Interaction Network Analysis

To determine the key *H. cordata* targets, common targets were used to build a PPI network using the STRING database (https://string-db.org/) and Cytoscape software. And the core target proteins were identified in the PPI network.

Go Analysis and KEGG Pathway Enrichment Analysis

The overlapped targets were further analyzed by the GO function analysis and KEGG enrichment analysis using the clusterProfiler package based on R language. The filtering thresholds for the retrieved results were $p < 0.05$ and $q < 0.05$.

Molecular Docking Simulation

The binding ability of key components and key targets was verified to explore the accurate binding modes through
molecular docking simulation. The PDB database (http://www.rcsb.org/) and the optimal models visualized using PyMOL (2.0) software (http://www.pymol.org/2/) and AutoDockVina software (http://vina.scripps.edu/) were used to perform the molecular docking of active components and core targets.

EXPERIMENT VALIDATION

Materials and Methods

Chemicals and Regents

Sodium new houttuynfonate (SNH, MW: 330.41, purity ≥ 98%), quercetin (MW: 302.24, purity ≥ 97%), and 2-undecanone (MW: 170.29, purity ≥ 99%) were purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Shanghai, China).

Cell Culture

A549 cells, obtained from the Cell Bank of the Chinese Academy of Sciences, were cultured in DMEM-H with 10% fetal bovine serum (Gibco, United States), 100 U/mL penicillin, and 100 ng/ml streptomycin with 5% CO₂ at 37°C. The EMT model of lipopolysaccharide (LPS)-induced A549 was reproduced in our study (Cui et al., 2019). For the EMT model, when the A549 cells reached 70–80% confluence on 6-well tissue culture plates, they were placed in DMEM-H supplemented with 1% fetal bovine serum for 12 h. Subsequently, the culture was replaced to DMEM-H with 2% fetal bovine serum and then treated with 10 μg/ml LPS (from Escherichia coli 0111: B4, Sigma-Aldrich, St. Louis, MO, United States) and SNH, quercetin, and 2-undecanone alone or in combination for up to 24 h, respectively.

Western Blot Analyses

The cells were lysed in RIPA lysis buffer (Beyotime, China) with 1% phenylmethylsulfonylfluoride (PMSF, Beyotime, China), 2% phosphorylated proteinase inhibitor (Beyotime, China), and 2% protease inhibitor (Beyotime, China). And 30 μg of the protein was separated using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (10%), and then was transferred onto a PVDF membrane. After blocking, the membranes were incubated overnight at 4°C with the primary antibody against β-actin (1:2,000, Affinity, United States), Phospho-AKT (1:1,000, Proteintech, United States), p44/42 MAPK (ERK1/2) (1:1,000, CST, United States of America), Phospho-p44/42 MAPK (ERK1/2) (1:1,000, CST, United States), Phospho-p38 MAPK (1:1,000, CST, United States), and TNF-α (1:1,000, CST, United States). Next, membranes were washed in TBS-T several times, and then were incubated for 2 h in horseradish peroxidase (HRP)-linked
anti-rabbit (1:2,000, CST, United States) or anti-mouse (1:2,000, CST, United States) at room temperature. After washing with TBS-T again, the protein bands were analyzed using ChemiScope 3500mini exposure instrument (Clinx Science Instruments Co., Ltd. Shanghai, China) with a chemiluminescence substrate.

Statistical Analysis
All values were expressed as mean ± standard deviation (SD), and data and analyses for graphing were processed with SPSS 25.0 statistical software and GraphPad Prism 8.0.2 software. Comparisons between groups were performed using one-way ANOVA. Values of $p < 0.05$ were considered statistically significant.

RESULTS
This study reveals the mechanism of the anti-pulmonary fibrosis pharmacological action of *H. cordata* by a TCM network pharmacology-based strategy and provides ideas for *H. cordata* for further drug development. This workflow is shown in Figure 1.

*H. cordata’s* Active Ingredients and Potential Target Prediction Results
*H. cordata’s* chemical constituents were collected from TCMSP. A total of 10 main components were candidated after removing the redundant ones from the literature and public databases. The 10 components were as follows: hyperoside, quercetin, rutin, heriguard, houttuynin, 2-undecanone, isoquercitrin, quercitrin, β-stigmasterol, and myrcene (*Table 1*). A total of 341 targets for the 10 chemical compositions were obtained after gene standardization and the elimination of repetitive values.

Feature Analysis of Active Compound–Drug Target Network
PF-related targets were collected from DisGeNET, GeneCards, OMIM, and Drugbank databases. After merging and deleting duplicate values, a total of 1,152 targets were obtained. As shown in Figure 2, 101 predicted targets were obtained after the intersection of drug-related targets and PF-related targets. The details of common target genes are shown in *Table 2*. 101 therapeutic targets were confirmed by the UniProt database, and a predicted target network of *H. cordata’s* major ingredient’s actions on PF was constructed using Cytoscape software (Figure 3).

PPI Network Analysis Results
A predicted PPI relationship network was obtained after the input of 101 predicted targets into the STRING platform and Cytoscape for topological analysis. MAPK1 (ERK2), TNF, AKT1, VEGFA, TP53, IL-1β, and IL-6 were advised to be the core (hub) node owing to a high network degree value, betweenness centrality, and closeness centrality in the PPI regulatory network (Figure 4).
GO Analysis and KEGG Pathway Enrichment Analysis of Shared Targets

With the clusterProfiler package based on R language and a filtering condition of \( p < 0.05 \) and \( q < 0.05 \), GO and KEGG pathway enrichment analyses of the 101 intersection targets were used to determine the biological functions of PF that were affected by \( H. \) cordata. GO enrichment items were composed of biological process (BP) terms, cell composition (CC) terms, and molecular function (MF) terms (Figure 5). The BP was related to the response to oxidative stress (GO: 0006979), cellular response to chemical stress (GO: 0062197), reactive oxygen species metabolic process (GO: 0072593), cellular response to oxidative stress (GO: 0034599), response to antibiotic (GO: 0046677), regulation of the reactive oxygen species metabolic process (GO: 2000377), response to lipopolysaccharide (GO: 0032496), and response to molecule of bacterial origin (GO: 0002237); in the part of CC, we obtained membrane raft (GO: 0044853), membrane microdomain (GO: 0098857), membrane region (GO: 0098589), vesicle lumen (GO: 0031983), caveola (GO: 0005901), secretory granule lumen (GO: 0034774), cytoplasmic vesicle lumen (GO: 0060205), and plasma membrane raft (GO: 0044853); in the aspect of MF, there were heme binding (GO: 0020037), tetrapyrrole binding (GO: 0046906), phosphatase binding (GO: 0019902), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO: 0019903), oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (GO: 0016712), and serine-type endopeptidase activity (GO: 0004252). The mechanism of \( H. \) cordata treatment...
of PF may be the result of the synergistic effects of multiple pathways. 101 targets were subjected to KEGG pathway enrichment analysis, with a total of 143 pathways, and the top 30 significantly enriched KEGG pathways were identified and selected for visualization (Figure 6). The action target main enriched pathway network is shown in Figure 7.

The Molecular Docking of Ingredient and Key Target Proteins

Three core target proteins (AKT1, MAPK1, and TNF-α) with high degrees were identified with nine active compounds (quercetin, hyperoside, rutin, heriguard, 2-undecanone, isoquercitrin, quercitrin, β-stigmasterol, and myrcene) by AutoDock Vina. According to the results of the molecular docking activity, the compounds selected generally had a moderate binding potential with a good medicinal reference value (Figure 8A). The docking scores were visualized using a heatmap (Figure 8B). Ultimately, three target proteins and three small molecule compounds with good docking affinity and higher content in H. cordata were used for subsequent experimental studies.

Experimental Demonstration In Vitro

Based on the results of network pharmacology and molecular docking, the anti-pulmonary fibrosis effect of 2-undecanone, sodium new houttuyfonate, and quercetin was necessary to be assessed with three protein-related pathways. According to the results of pre-experiment and literature data, 0.2 mM 2-undecanone, 0.3 mM sodium new houttuyfonate, and 0.05 mM quercetin were used in subsequent research. As the results were obtained, the expression of p-AKT, AKT, p44/42 MAPK (ERK1/2), p-p44/42 MAPK (ERK1/2), p-p38 MAPK, and TNF-α protein in the drug group was significantly decreased compared with that in the model group (p < 0.05 or p < 0.01) (Figures 9A–G). Our results showed that 2-undecanone, sodium new houttuyfonate,
and quercetin inhibited the production of fibrosis in LPS-induced A549 cells.

**DISCUSSION**

PF is a progressive and severe condition characterized by mesenchymal cell proliferation and differentiation, ECM deposition, and remodeling of the lung parenchyma and airways. Although progress has been made in the research on PF, our understanding of its pathological mechanism remains rudimentary. There is still no complete cure for PF, and current therapies merely act to delay but not completely stop the progression of the disease.

*H. cordata*, a Chinese herb with special odor, is mainly used to treat bronchitis and upper respiratory tract infection. And studies have reported that it can inhibit rapid PF by upregulating IFN-γ and inhibiting the TGF-β1/Smad pathway (Du et al., 2012). 2-Undecanone, houttuynin, and quercetin are the main constituents of *H. cordata*. Houttuynin is the easily polymerized major constituent of the volatile oil, and the content is usually about 15%, which was first isolated from *H. cordata* in 1952 (Pan et al., 2010). Because houttuynin was unstable in chemical characteristics, sodium new houttuynate (sodium lauroyl-α-hydroxyethyl sulfonate, C_{14}H_{27}NaO_{5}S, MW = 330.4), an adduct compound of houttuynin and sodium bisulfite, was developed and put in use. Sodium new houttuynate has better water solubility and stability and can be transformed into houttuynin under physiological conditions. Previous studies have shown that the lung is the target organ of houttuynin, and it has good therapeutic effects on pneumonia (Deng et al., 2012). Also, sodium new houttuynate is an effective clinical therapeutic agent applied to respiratory infection and inflammation such as acute or chronic bronchitis and pneumonia. 2-Undecanone is used as a standard marker for the quality control of *H. cordata* in the Chinese pharmacopoeia, and its content is usually about 17.0–27.5% (Yu-hong et al., 2015). Studies have shown that 2-undecanone performed various types of pharmacological functions, including anti-inflammatory and antitumor effects (Chen et al., 2014; Lou et al., 2019). Quercetin is one of the major flavonoid-active components in *H. cordata*, and the content is usually about 0.50 mg/g (Xiao-lei and Xiao-yin, 2013), which could overexpress the FasL receptor and caveolin-1 expression, reducing AKT activation and eliminating apoptosis resistance in IPF (Hohmann et al., 2019). Quercetin increases the Nrf2
activity to defend against oxidation, restore the disturbed redox balance, and reduce inflammation (Veith et al., 2017). As has been reported, quercetin can also reduce the expression of IL-6, TNF-α, and IL-1β in the bronchoalveolar lavage fluid of bleomycin-induced PF in vivo (Baowen et al., 2010).

Our results analyzed the ingredients in *H. cordata*, as well as the functions and potential targets against PF. According to the topological property analysis of the “drug–disease” network and the results of the PPI network analysis, the targets of the action of *H. cordata* were members of the mitogen-activated protein kinase (MAPK) family, TNF, AKT, or the cytokine VEGF. The results of the GO functional enrichment analysis revealed that *H. cordata* is mainly involved in signal transduction, inflammatory immunity, regulation of chemokine production, etc. The KEGG enrichment analysis showed that the possible pathways involved in the anti-pulmonary fibrosis of *H. cordata* mainly included the phosphatidylinositol-3-kinase (PI3K)/Akt signaling pathway, MAPK signaling pathway, TNF signaling pathway, IL-17 signaling pathway, HIF-1 signaling pathway, and NOD-like receptor signaling pathway. All the above signaling pathways are related to inflammation and immune responses, indicating that *H. cordata* exerts immunomodulatory and anti-inflammatory effects through multiple pathways, exactly in accordance with our previous study which shows that sodium houttuyniate reduces BLM-induced elevation of inflammatory cytokines such as IL-1, IL-6, and TNF-α in mice (Shen et al., 2021). The PI3K/Akt signaling pathway mainly regulates cell proliferation, inflammation, and survival, and maintains the biological properties of malignant cells. PI3K, consisting of a regulatory subunit, p85, and a catalytic subunit, p110, primarily exist in the cytoplasm. Akt, also known as the protein kinase B (PKB), regulates and controls cell proliferation and apoptosis. After PI3K activation by tyrosine kinases, PIP3 was generated on the plasma membrane to interact with the PH domain of Akt, and

---

**FIGURE 8 | (A)** Molecular docking results of the “bioactive compound-target gene.” **(B)** Heatmap of the docking scores of the main chemical constituents of *H. cordata* and the target proteins.
FIGURE 9 | Effects of 2-undecanone, sodium new houttuynate, and quercetin on the protein expression of AKT, p-AKT, p44/42 MAPK (ERK1/2), p-p44/42 MAPK, and TNF-α of LPS-induced A549 cells (A–G). #p < 0.05, ##p < 0.01, compared with the control group. *p < 0.05, **p < 0.01, compared with the LPS group.
Thr^{308} and Ser^{473} of Akt will be phosphorylated with the help of 3-phosphoinositide-dependent protein kinase 1 (PDK1) and PDK2, Akt-activated (Assinder et al., 2009). PI3K/Akt contributes to the development and progression of PF by upregulating cell growth and collagen expression (Lu et al., 2020). TNF-α, a key regulator of inflammation, could initiate and drive many pulmonary pathological diseases by inducing the accumulation of inflammatory cells, causing oxidative and nitrosative stress, airway hyperactivity, and tissue remodeling (Blaser et al., 2016). TNF-α stimulates epithelial cell proliferation and contributes to epithelial thickening and PF (Sasaki et al., 2000). MAPKs, serine–threonine protein kinases, have been proven to control cellular processes associated with fibrosis, such as myofibroblast transformation and others (Xu et al., 2004). The extracellular signal–regulated kinases 1 and 2 (ERK1/2) cascade can regulate cell proliferation, differentiation, EMT, and tumorigenesis. The activation of ERK signaling causes morphological changes and the downregulation of E-cadherin expression in epithelial cells (Grände et al., 2002). Next, molecular docking studies for MAPK1, AKT1, and TNF-α were performed using the active constituents 2-undecanone, quercitrin, β-stigmasterol, myrcene, isoquercitrin, heriguard, rutin, quercetin, and hyperoside to evaluate the thermodynamic binding effects of proteins and ligands. The results showed that the target proteins and components had good binding effects. And quercetin showed great binding strength with MAPK1, AKT1, and TNF-α, which may play an essential role in PF.

LPS, an endotoxin component of Gram-negative bacilli as an inflammatory inducer, is a vital promoter of acute lung injury (ALI) as well as promoting EMT formation in various cell types including alveolar epithelial cells (AECs) (Dong et al., 2017; Xiao et al., 2020). A549 cells were added to LPS coculture to induce EMT validating the predicted outcome of network pharmacology. Evidence showed that quercetin was well validated by its docking to IL-6, TNF, and IL-1β proteins (Yu et al., 2021). These findings strikingly supported the molecular docking and experimental results of our study that quercetin may exert anti-PF effects by targeted binding to TNF. And sodium houttuynonate inhibited the expression of inflammatory cytokine TNF-α, which was consistent with our previous findings in bleomycin-induced pulmonary fibrosis in mice. Results from our study revealed the potential mechanism of *H. cordata* and suggested that *H. cordata* has a clinical application value in attenuating PF because of its effect in inhibiting the expression of AKT, p-AKT, p44/42 MAPK (ERK1/2), p-p44/42 MAPK (ERK1/2), p-p38 MAPK, and TNF-α via the PI3K/AKT, MAPK, and TNF signaling pathways.

However, the mechanism needs more investigation *in vitro and in vivo* models.

**CONCLUSION**

Our present study has important implications for the current understanding of the molecular mechanism of *H. cordata* in anti-pulmonary fibrosis, which involves multicomponents, multi-targets, and multi-pathways. An in-depth study should be considered by taking *H. cordata* as a novel anti-pulmonary fibrotic drug.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding author.

**AUTHOR CONTRIBUTIONS**

Y-HS: conception and design, methodology, data curation, visualization, investigation, supervision, validation, writing—reviewing and editing, project administration, and funding acquisition. D-WZ: investigation, methodology, data curation, data and image processing, visualization, validation, writing—original draft preparation, and writing—reviewing and editing. QY: software, data curation, data and image processing, visualization, and validation. J-JS: conceptualization, methodology, software, data curation, data and image processing, and visualization. All authors contributed to and have approved the final manuscript.

**FUNDING**

This work was supported by the Foundation of Shanghai Municipal Education Commission (No. 09JW08), the “Out-oriented Xinglin Talent Program.”

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.733618/full#supplementary-material

**REFERENCES**

Assinder, S. J., Dong, Q., Kovacevic, Z., and Richardson, D. R. (2009). The TGF-Beta, PI3K/Akt and PTEN Pathways: Established and Proposed Biochemical Integration in Prostate Cancer. *Biochem. J.* 417 (2), 411–421. doi:10.1042/bj20081610

Baowen, Q., Yulin, Z., Xin, W., Wenjing, X., Hao, Z., Zhizhi, C., et al. (2010). A Further Investigation Concerning Correlation between Anti-fibrotic Effect of Liposomal Quercetin and Inflammatory Cytokines in Pulmonary Fibrosis. *Eur. J. Pharmacol.* 642 (1-3), 134–139. doi:10.1016/j.ejphar.2010.05.019

Blaser, H., Dostert, C., Mak, T. W., and Brenner, D. (2016). TNF and ROS Crosstalk in Inflammation. *Trends Cell Biol.* 26 (4), 249–261. doi:10.1016/j.tcb.2015.12.002

Chen, J., Wang, W., Shi, C., and Fang, J. (2014). A Comparative Study of Sodium Houttuynonate and 2-undecanone for Their *In Vitro* and *In Vivo* Anti-inflammatory Activities and Stabilities. *Int. J. Mol. Sci.* 15 (12), 22978–22994. doi:10.3390/ijms151222978
